Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE.
BROMPHENIRAMINE MALEATE vs TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
1 tablet (triprolidine 2.5 mg/pseudoephedrine 60 mg) orally every 4 to 6 hours; maximum 4 tablets per 24 hours.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Triprolidine: 3-5 hours (terminal). Pseudoephedrine: 5-8 hours (terminal, pH-dependent; urine pH 8: ~13 hours, pH 5: ~3 hours). Clinical: normal renal function.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Triprolidine: ~80% renal (mostly metabolites, <5% unchanged). Pseudoephedrine: ~70-90% renal (43-96% unchanged, depends on urine pH; acidic urine increases elimination, alkaline decreases). Biliary/fecal: negligible for both.
Category C
Category A/B
Antihistamine
Antihistamine